

Cilosta[®]

Cilostazol

Description

Cilosta[®] : Each tablet contains Cilostazol INN 100 mg.

Pharmacology

Cilosta[®] is a preparation of Cilostazol which is a quinolinone derivative. The mechanism of action is to specifically inhibit cellular phosphodiesterase III (PDE III) and suppress cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation.

Indication

Cilosta[®] is indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance.

Dosage and Administration

The recommended dosage of **Cilosta[®]** is 100 mg bid, taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg bid should be considered during coadministration of Fluconazole, Ketoconazole, Itraconazole, Erythromycin, Clarithromycin, Fluvoxamine, Fluoxetine, Nefazodone, Sertraline and Diltiazem.

Contraindication

Cilostazol is contraindicated in patients with congestive heart failure of any severity. Cilostazol is also contraindicated in patients with known or suspected hypersensitivity to any of its components.

Precaution

Cilostazol should be used with caution in patients with any degree of heart failure. There is no information with respect to the efficacy or safety of the concurrent use of Cilostazol and Clopidogrel.

Drug Interaction

Pharmacokinetic studies have demonstrated that Omeprazole and Erythromycin significantly increased the systemic exposure of Cilostazol and/or its major metabolites. Population pharmacokinetic studies showed higher concentrations of Cilostazol among patients concurrently treated with Diltiazem.

Side Effect

The most common side effects are headache, diarrhoea, vomiting, leg cramps, rash etc. The less frequent side effects are anorexia and edema.

Use in Special Population

Pregnancy : There are no adequate and well controlled studies in pregnant women.

Lactation : Transfer of Cilostazol into milk has been reported in experimental animals. Because of the potential risk to nursing infants, a decision should be made to discontinue nursing or to discontinue Cilostazol. *Paediatric use*: The safety and effectiveness of Cilostazol in paediatric patients have not been established.

Storage Condition

Store in a cool & dry place, protected from light and moisture.

How Supplied

Cilosta[®] : Each box contains 30 tablets in blister packs.

Manufactured by :



SQUARE

PHARMACEUTICALS LTD.
BANGLADESH

® Registered Trade Mark

Revision no.:00